nach oben

Hepatology International

Erschienen in:

01.06.2009 | Original Article

High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection

verfasst von: Chun-Jen Liu, Pei-Jer Chen, Ming-Yang Lai, Chen-Hua Liu, Chi-Lin Chen, Jia-Horng Kao, Ding-Shinn Chen

Erschienen in: Hepatology International | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Adiponectin possesses anti-inflammatory and insulin-sensitizing properties. Little is known about the role of adiponectin in hepatitis B-related liver disease.

Methods

Serum adiponectin and hepatitis B viral factors were cross-sectionally assayed in 280 patients with chronic hepatitis B virus (HBV) infection including 120 patients with chronic HBV infection, 40 patients with cirrhosis, and 120 patients with hepatocellular carcinoma (HCC); 116 healthy adults were used as controls. The dynamics of serum adiponectin level was also studied longitudinally in 25 patients with hepatitis B e antigen (HBeAg) seroconversion (SC).

Results

We found that serum adiponectin level in patients with chronic HBV infection was similar to that in healthy controls and was significantly lower than patients with cirrhosis and HCC. In univariate analysis, high serum adiponectin level significantly correlated with the presence of HBV-related cirrhosis or HCC, abnormal serum ALT level, and HBV genotype C. Multivariate analysis revealed that high serum adiponectin level significantly correlated with the development of HCC. Serum adiponectin levels remained stationary in patients experiencing HBeAg SC.

Conclusions

Our findings suggest that HBV infection itself does not affect adiponectin levels. Serum adiponectin level correlates with the progression of HBV-related liver diseases but not with the development of HBeAg SC.

Kao JH, Chen DS. Global control of hepatitis B virus. Lancet Infect Dis 2002;2:395–403. doi:10.1016/S1473-3099(02)00315-8 PubMedCrossRef

Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733–1745. doi:10.1056/NEJM199712113372406 PubMedCrossRef

Liu CJ, Chen PJ, Lai MY, Kao JH, Chang CF, Wu HL, et al. A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology 2003;124:80–90. doi:10.1053/gast.2003.50003 PubMedCrossRef

Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein ACRP30 enhances hepatic insulin action. Nat Med 2001;7:947–953. doi:10.1038/90992 PubMedCrossRef

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83. doi:10.1006/bbrc.1999.0255 PubMedCrossRef

Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipocyte-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697–10703. doi:10.1074/jbc.271.18.10697 PubMedCrossRef

Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126–1133. doi:10.2337/diabetes.50.5.1126 PubMedCrossRef

Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:200–206. doi:10.1210/jc.2003-031315 PubMedCrossRef

Gil-Campos M, Canete R, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004;23:963–974. doi:10.1016/j.clnu.2004.04.010 PubMedCrossRef

10.

Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alfa in KK-Ay-obese mice. Hepatology 2004;40:177–184. doi:10.1002/hep.20282 PubMedCrossRef

11.

Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003;125:1796–1807. doi:10.1053/j.gastro.2003.08.029 PubMedCrossRef

12.

Custro N, Carroccio A, Ganci A, Scafidi V, Campagna P, Di Prima L, et al. Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab 2001;27:476–481PubMed

13.

Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003;125:1695–1704. doi:10.1053/j.gastro.2003.08.032 PubMedCrossRef

14.

Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005;43:929–936. doi:10.1016/j.jhep.2005.05.030 PubMedCrossRef

15.

Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005;54:117–121. doi:10.1136/gut.2003.037010 PubMedCrossRef

16.

Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005;43:235–242. doi:10.1016/j.jhep.2005.02.044 PubMedCrossRef

17.

Neumeier M, Hellerbrand C, Gäbele E, Buettner R, Bollheimer C, Weigert J, et al. Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis. World J Gastroenterol 2006;12:5490–5494PubMed

18.

Petit JM, Minello A, Jooste V, Bour JB, Galland F, Duvillard L, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus infected patients. J Clin Endocrinol Metab 2005;90:2240–2243. doi:10.1210/jc.2004-1266 PubMedCrossRef

19.

Siagris D, Vafiadis G, Michalaki M, Lekkou A, Starakis I, Makri M, et al. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat 2007;14:577–583. doi:10.1111/j.1365-2893.2007.00850.x PubMedCrossRef

20.

Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004;287:E82–E92. doi:10.1152/ajpendo.00494.2003 PubMedCrossRef

21.

Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3 but not genotype 1 infection. Am J Gastroenterol 2005;100:2717–2723. doi:10.1111/j.1572-0241.2005.00311.x PubMedCrossRef

22.

Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91–100PubMed

23.

Yokoyama H, Hirose H, Ohgo H, Saito I. Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. J Hepatol 2004;41:19–24. doi:10.1016/j.jhep.2004.03.003 PubMedCrossRef

24.

Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, et al. Associations between plasma adiponectin concentrations and liver histology in patients with non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006;64:679–683. doi:10.1111/j.1365-2265.2006.02527.x CrossRef

25.

Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in non-alcoholic fatty liver disease. Eur J Endocrinol 2005;152:113–118. doi:10.1530/eje.1.01821 PubMedCrossRef

26.

Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Fagà E, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005;42:1175–1183. doi:10.1002/hep.20896 PubMedCrossRef

27.

Musso G, Gambino R, Biroli G, Carello M, Fagà E, Pacini G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005;100:2438–2446. doi:10.1111/j.1572-0241.2005.00297.x PubMedCrossRef

28.

Hui CK, Zhang HY, Lee NP, Chan W, Yueng YH, Leung KW, et al. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J Hepatol 2007;47:191–202. doi:10.1016/j.jhep.2007.02.023 PubMedCrossRef

29.

Kaser S, Moschen A, Kaser A, Ludwiczek O, Ebenbichler CF, Vogel W, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 2005;258:274–280. doi:10.1111/j.1365-2796.2005.01543.x PubMedCrossRef

30.

Tacke F, Wüstefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005;42:666–673. doi:10.1016/j.jhep.2004.12.024 PubMedCrossRef

31.

Lu JY, Chuang LM, Yang WS, Tai TY, Lai MY, Chen PJ, et al. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int 2005;25:752–759. doi:10.1111/j.1478-3231.2005.1007.x PubMedCrossRef

32.

Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522–1527. doi:10.1053/jhep.2002.33638 PubMedCrossRef

33.

Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, et al. Combined real-time PCR quantification and signature single nucleotide polymorphism genotyping of hepatitis B virus in one-tube reaction. J Hepatol 2004;41:659–666. doi:10.1016/j.jhep.2004.06.031 PubMedCrossRef

34.

Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264–274PubMed

Titel: High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection
verfasst von: Chun-Jen Liu
Pei-Jer Chen
Ming-Yang Lai
Chen-Hua Liu
Chi-Lin Chen
Jia-Horng Kao
Ding-Shinn Chen
Publikationsdatum: 01.06.2009
Verlag: Springer-Verlag
Erschienen in: Hepatology International / Ausgabe 2/2009
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-008-9111-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Liver cirrhosis and hepatocellular carcinoma in hepatic vena cava disease, a liver disease caused by obstruction of inferior vena cava

Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)

Induction of tropomyosin during hepatic stellate cell activation and the progression of liver fibrosis

The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B

Two cases of hepatocellular adenomatosis treated with transcatheter arterial embolization

Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin